161 related articles for article (PubMed ID: 26852363)
1. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.
Schiemann K; Mallinger A; Wienke D; Esdar C; Poeschke O; Busch M; Rohdich F; Eccles SA; Schneider R; Raynaud FI; Czodrowski P; Musil D; Schwarz D; Urbahns K; Blagg J
Bioorg Med Chem Lett; 2016 Mar; 26(5):1443-51. PubMed ID: 26852363
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
[TBL] [Abstract][Full Text] [Related]
3. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Dale T; Clarke PA; Esdar C; Waalboer D; Adeniji-Popoola O; Ortiz-Ruiz MJ; Mallinger A; Samant RS; Czodrowski P; Musil D; Schwarz D; Schneider K; Stubbs M; Ewan K; Fraser E; TePoele R; Court W; Box G; Valenti M; de Haven Brandon A; Gowan S; Rohdich F; Raynaud F; Schneider R; Poeschke O; Blaukat A; Workman P; Schiemann K; Eccles SA; Wienke D; Blagg J
Nat Chem Biol; 2015 Dec; 11(12):973-980. PubMed ID: 26502155
[TBL] [Abstract][Full Text] [Related]
4. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
5. Binding patterns and structure-activity relationship of CDK8 inhibitors.
Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
[TBL] [Abstract][Full Text] [Related]
6. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
[TBL] [Abstract][Full Text] [Related]
7. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
Xi M; Chen T; Wu C; Gao X; Wu Y; Luo X; Du K; Yu L; Cai T; Shen R; Sun H
Eur J Med Chem; 2019 Feb; 164():77-91. PubMed ID: 30594029
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
Mallinger A; Schiemann K; Rink C; Stieber F; Calderini M; Crumpler S; Stubbs M; Adeniji-Popoola O; Poeschke O; Busch M; Czodrowski P; Musil D; Schwarz D; Ortiz-Ruiz MJ; Schneider R; Thai C; Valenti M; de Haven Brandon A; Burke R; Workman P; Dale T; Wienke D; Clarke PA; Esdar C; Raynaud FI; Eccles SA; Rohdich F; Blagg J
J Med Chem; 2016 Feb; 59(3):1078-101. PubMed ID: 26796641
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent and selective CDK8 inhibitors through FBDD approach.
Han X; Jiang M; Zhou C; Zhou Z; Xu Z; Wang L; Mayweg AV; Niu R; Jin TG; Yang S
Bioorg Med Chem Lett; 2017 Sep; 27(18):4488-4492. PubMed ID: 28802632
[TBL] [Abstract][Full Text] [Related]
11. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
He LJ; Zhu YB; Fan QZ; Miao DD; Zhang SP; Liu XP; Zhang C
Bioorg Med Chem Lett; 2019 Feb; 29(4):549-555. PubMed ID: 30630717
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
Wang T; Yang Z; Zhang Y; Yan W; Wang F; He L; Zhou Y; Chen L
Eur J Med Chem; 2017 Mar; 129():275-286. PubMed ID: 28231524
[TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
15. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
[TBL] [Abstract][Full Text] [Related]
16. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.
Zhang L; Cheng C; Li J; Wang L; Chumanevich AA; Porter DC; Mindich A; Gorbunova S; Roninson IB; Chen M; McInnes C
J Med Chem; 2022 Feb; 65(4):3420-3433. PubMed ID: 35114084
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives.
Ono K; Banno H; Okaniwa M; Hirayama T; Iwamura N; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
Bioorg Med Chem; 2017 Apr; 25(8):2336-2350. PubMed ID: 28302507
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors.
Lv X; Tian Y; Li S; Cheng K; Huang X; Kong H; Liao C; Xie Z
Curr Med Chem; 2020; 27(32):5429-5443. PubMed ID: 30947649
[TBL] [Abstract][Full Text] [Related]
19. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
Solum E; Hansen TV; Aesoy R; Herfindal L
Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
[TBL] [Abstract][Full Text] [Related]
20. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
